6312-73-8

Basic information

• Product Name: 5-BROMO-6-AMINOURACIL
• Synonyms: 6-amino-5-bromouracil;SPECS AB-323/25048333;5-BROMO-6-AMINOURACIL;6-AMINO-5-BROMO-1H-PYRIMIDINE-2,4-DIONE;2,4(1H,3H)-Pyrimidinedione, 6-amino-5-bromo-;6-amino-5-bromopyrimidine-2,4(1H,3H)-dione;Einecs 228-638-7;Nsc 27652
• CAS NO: 6312-73-8
• Molecular Formula: C₄H₄BrN₃O₂
• Molecular Weight: 206
• EINECS: 228-638-7
• Mol File: 6312-73-8.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 432.8oC at 760 mmHg
• Flash Point: 215.6oC
• Appearance: /
• Density: 2.005 g/cm³
• Vapor Pressure: 1.07E-07mmHg at 25°C
• Refractive Index: 1.559
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 5-BROMO-6-AMINOURACIL(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-6-AMINOURACIL(6312-73-8)
• EPA Substance Registry System: 5-BROMO-6-AMINOURACIL(6312-73-8)

Safety Data

• Hazardous Substances Data: 6312-73-8(Hazardous Substances Data)

Usage

General Description

5-Bromo-6-aminouracil is a chemical compound with the molecular formula C4H4BrN3O2. It is a brominated derivative of uracil and is often used in the study of nucleic acids and their interactions. 5-BROMO-6-AMINOURACIL is known to have antimicrobial activity and has been used in the development of antimicrobial agents. It is also used as a precursor in the synthesis of various pharmaceuticals and agricultural chemicals. Additionally, 5-Bromo-6-aminouracil has been investigated for its potential use in cancer treatment due to its ability to inhibit the growth of tumor cells. 5-BROMO-6-AMINOURACIL is a valuable tool in biochemical and pharmaceutical research.

InChI:InChI=1/C19H29FN2S/c1-2-3-4-9-14-21-19(23)22(17-11-6-7-12-17)15-16-10-5-8-13-18(16)20/h5,8,10,13,17H,2-4,6-7,9,11-12,14-15H2,1H3,(H,21,23)

Upstream product

• 873-83-6 4-Amino-2,6-dihydroxypyrimidine 
• 1439-10-7 4-amino-5-bromopyrimidine 
• 2240-25-7 6-amino-5-bromo-1H-pyrimidin-2-one 

Downstream Products

• 25507-29-3 6-amino-5-benzylaminopyrimidine-2,4(1H,3H)-dione 
• 89721-62-0 6-amino-5-(2-amino-phenylthio)-2,4(1H,3H)-pyrimidinedione 

Relevant articles and documents

Fragment Discovery for the Design of Nitrogen Heterocycles as Mycobacterium tuberculosis Dihydrofolate Reductase Inhibitors

Fragment-based drug design was used to identify Mycobacterium tuberculosis (Mtb) dihydrofolate reductase (DHFR) inhibitors. Screening of ligands against the Mtb DHFR enzyme resulted in the identification of multiple fragment hits with IC50 values in the range of 38–90 μM versus Mtb DHFR and minimum inhibitory concentration (MIC) values in the range of 31.5–125 μg/mL. These fragment scaffolds would be useful for anti-tubercular drug design.

Synthesis and enzymatic evaluation of xanthine oxidase-activated prodrugs based on inhibitors of thymidine phosphorylase

A series of xanthine oxidase-activated prodrugs of known inhibitors of thymidine phosphorylase are described. These prodrugs were oxidised by xanthine oxidase at C-2 and/or C-4 of the uracil ring to generate the desired TP inhibitor. The scheme shows the prodrug of TPI. A series of xanthine oxidase-activated prodrugs of known inhibitors of thymidine phosphorylase has been designed and synthesised to introduce tumour selectivity. These prodrugs were oxidised by xanthine oxidase at C-2 and/or C-4 of the uracil ring to generate the desired TP inhibitor.